Click on the logo to connect to the complete list on PubMed.

 
 

Publications (complete list in chronological order):

 

1.      Mari Hirvinen, Cristian Capasso, Mariangela Garofalo, Dmitry Romanyuk, Lukasz Kuryk, Akseli Hemminki, Iulia Diaconu, Kilian Guse, Dario Greco, Vincenzo Cerullo*. DAI-armed vaccinia virus displays enhanced efficacy and anti-tumor immunity in humanized mice bearing xenograft tumors. Mol Ther Oncolytics. 2016 Mar 23;3:16002. doi: 10.1038/mto.2016.2. eCollection 2016.

 

2.      Ruan MZ, Cerullo V, Cela R, Clarke C, Lundgren-Akerlund E, Barry MA, Lee BH. Treatment of osteoarthritis using a helper-dependent adenoviral vector retargeted to chondrocytes. Mol Ther Methods Clin Dev. 2016 Mar 9;3:16008. doi: 10.1038/mtm.2016.8. eCollection 2016.

 

3.      Cristian Capasso, Mari Hirvinen, Mariangela Garofalo, Dmitry Romanyuk, Lukasz Kuryk, Maxim Antopolsky, Arto Urtti, Vincenzo Cerullo*. Oncolytic adenovirus loaded with MHC-I restricted peptide as platform for oncolytic vaccine. Oncoimmunology. 2015 Oct 29;5(4):e1105429. eCollection 2016 Apr.

 

4.      Mariangela Garofalo, Lukasz Kuryk, Mari Hirvinen, Cristian Capasso, Dmitry Romanyuk, Barbara Iovine, Mara Bevilacqua, Vincenzo Cerullo*. Oncolytic adenovirus coated with a synthetic carnosine-derived peptide enhances anti-tumor activity in xerograph model of human solid tumors. Mol Cancer Ther. 2016 Apr;15(4):651-60. doi: 10.1158/1535-7163.MCT-15-0559. Epub 2016 Feb 9.

 

5.      Lukasz Kuryk, Lotta Vassilev, Sari Pesonen, Elina Haavisto, Tuuli Ranki, Antti Vuolanto, Mariangela Garofalo, Mari Hirvinen, Cristian Capasso, Dima Romanyuk, Vincenzo Cerullo*. Oncolytic adenovirus ONCOS-102 combined with Pemetrexed disodium, Cisplatin and Carboplatin-based chemotherapy modalities presents antineoplastic activity against mesothelioma. Int J Cancer. 2016 Oct 15;139(8):1883-93. doi: 10.1002/ijc.30228. Epub 2016 Jun 24.

 

6.      Taipale K, Liikanen I, Juhila J, Turkki R, Tähtinen S, Kankainen M, Vassilev L, Ristimäki A, Koski A, Kanerva A, Diaconu I, Cerullo V, Vähä-Koskela M, Oksanen M, Linder N, Joensuu T, Lundin J, Hemminki A. Chronic Activation of Innate Immunity Correlates With Poor Prognosis in Cancer Patients Treated With Oncolytic Adenovirus. Mol Ther. 2015 Aug 27

 

7.      Bramante S, Kaufmann JK, Veckman V, Liikanen I, Nettelbeck DM, Hemminki O, Vassilev L, Cerullo V, Oksanen M, Heiskanen R, Joensuu T, Kanerva A, Pesonen S, Matikainen S, Vähä-Koskela M, Koski A, Hemminki A. Treatment of melanoma with a serotype 5/3 chimeric oncolytic adenovirus coding for GM-CSF: Results in vitro, in rodents and in humans. Int J Cancer. 2015 Oct 1;137(7):1775-83

 

8.      Markus Vähä-Koskela, Siri Tähtinen, Susanna Grönberg-Vähä-Koskela, Kristian Taipale, Dipongkor Saha, Maiju Merisalo-Soikkeli, Marko Ahonen, Noora Rouvinen-Lagerström, Mari Hirvinen, Ville Veckman, Sampsa Matikainen, Fang Zhao, Päivi Pakarinen, Jarmo Salo, Anna Kanerva, Vincenzo Cerullo & Akseli Hemminki. Overcoming tumor resistance by heterologous adeno-poxvirus combination therapy. Molecular Therapy — Oncolytics 1, 14006 (2015)

 

9.      Lisa Farzad, Vincenzo Cerullo, Shigeki Yagyu, Terry Bertin, Akseli Hemminki, Cliona Rooney, Brendan Lee, Masataka Suzuki. Combinatorial treatment with Oncolytic Adenovirus and Helper-dependent Adenovirus Augments Adenoviral Cancer Gene Therapy. Molecular Therapy — Oncolytics 1, 14008.

 

10.   Mari Hirvinen, Maria Rajecki, Mika Kapanen, Suvi Parviainen, Noora Rouvinen-Lagerström, Iulia Diaconu, Akseli Hemminki, Vincenzo Cerullo*. Immunological effects of a TNF-alpha armed oncolytic adenovirus. Hum Gene Ther. 2015 Mar;26(3):134-44. IF=4.3

 

11.   Nishio N, Diaconu I, Liu H, Cerullo V, Caruana I, Hoyos V, Bouchier-Hayes L, Savoldo B, Dotti G. Armed Oncolytic Virus Enhances Immune Functions of Chimeric Antigen Receptor-Modified T Cells in Solid Tumors. Cancer Res. 2014 Jul 24. IF=9.2

 

12.   Parviainen S, Ahonen M, Diaconu I, Kipar A, Siurala M, Vähä-Koskela M, Kanerva A, Cerullo V*, Hemminki A. GMCSF-armed vaccinia virus induces an antitumor immune response. Int J Cancer. 2014 Jul 8. IF=5.0

 

13.   Siurala M, Bramante S, Vassilev L, Hirvinen M, Parviainen S, Tähtinen S, Guse K, Cerullo V, Kanerva A, Kipar A, Vähä-Koskela M, Hemminki A. Oncolytic adenovirus and doxorubicin-based chemotherapy results in synergistic antitumor activity against soft-tissue sarcoma. Int J Cancer. 2014 Jun 27. IF=5.0

 

14.   Capasso C, Garofalo M, Hirvinen M, Cerullo V*. The evolution of adenoviral vectors through genetic and chemical surface modifications. Viruses. 2014 Feb 17;6(2):832-55. IF=3.4

 

15.   Cristian Capasso, Mari Hirvinen, Cerullo Vincenzo*. Chemical modification of virus's surface for gene therapy. Biomedicine.

 

16.   Parviainen S, Ahonen M, Vähä-Koskela M, Holm SL, Hemminki A*, Cerullo V*. CD40-ligand and tdTomato armed vaccinia virus for induction of anti-tumor immune response and tumor imaging.  Gene Therapy. Gene Ther. 2014 Feb;21(2):195-204. IF=4.3

 

17.   Bramante S, Koski A, Kipar A, Diaconu I, Liikanen I, Hemminki O, Vassilev L, Parviainen S, Cerullo V, Pesonen SK, Oksanen M, Heiskanen R, Rouvinen-Lagerström N, Merisalo-Soikkeli M, Hakonen T, Joensuu T, Kanerva A, Pesonen S, Hemminki A. Serotype chimeric oncolytic adenovirus coding for GM-CSF for treatment of sarcoma in rodents and humans. Int J Cancer. 2013 Dec 24. IF=6.1

 

18.   Hirvinen M, Heiskanen R, Oksanen M, Pesonen S, Liikanen I, Joensuu T, Kanerva A, Cerullo V*, Hemminki A. Fc-gamma receptor polymorphisms as predictive and prognostic factors in patients receiving oncolytic adenovirus treatment. J Transl Med. 2013 Aug 21;11(1):193. IF=3.4

 

19.   Leggiero E, Astone D, Cerullo V, Lombardo B, Mazzaccara C, Labruna G, Sacchetti L, Salvatore F, Croyle M, Pastore L. PEGylated helper-dependent adenoviral vector expressing human Apo A-I for gene therapy in LDLR-deficient mice. Gene Ther. 2013 Jul 25. IF=4.3

 

20.   Liikanen I, Ahtiainen L, Hirvinen ML, Bramante S, Cerullo V, Nokisalmi P, Hemminki O, Diaconu I, Pesonen S, Koski A, Kangasniemi L, Pesonen SK, Oksanen M, Laasonen L, Partanen K, Joensuu T, Zhao F, Kanerva A, Hemminki A. Oncolytic adenovirus with temozolomide induces autophagy and antitumor immune responses in cancer patients. Mol Ther. 2013 Jun;21(6):1212-23. IF= 7.04

 

21.   Kanerva A, Nokisalmi P, Diaconu I, Koski A, Cerullo V, Liikanen I, Tähtinen S, Oksanen M, Heiskanen R, Pesonen S, Joensuu T, Alanko T, Partanen K, Laasonen L, Kairemo K, Pesonen S, Kangasniemi L, Hemminki A. Antiviral and antitumor T-cell immunity in patients treated with GM-CSF-coding oncolytic adenovirus. Clin Cancer Res. 2013 May 15;19(10):2734-44. IF=7.8

 

22.   Hirvinen M, Cerullo V*. Genetic diversity and tumor immunosurvelliance. J Thorac Dis. 2013 Feb;5(1):6-7.

 

23.   Cerullo V*, Vähä-Koskela M, Hemminki A. Oncolytic adenoviruses: A potent form of tumor immunovirotherapy. Oncoimmunology. 2012 Sep 1;1(6):979-981.

 

24.   Cerullo V*, Koski A, Vähä-Koskela M, Hemminki A. Oncolytic adenoviruses for cancer immunotherapy: data from mice, hamsters, and humans. Adv Cancer Res.2012;115:265-318.  IF=6.3

 

25.   Guse K, Suzuki M, Sule G, Bertin TK, Tyynismaa H, Ahola-Erkkilä S, Palmer D, Suomalainen A, Ng P, Cerullo V, Hemminki A, Lee B. Capsid-modified adenoviral vectors for improved muscle-directed gene therapy. Hum Gene Ther. 2012 Oct;23(10):1065-70. IF=4.0

 

26.   D'Errico S, Oliviero G, Amato J, Borbone N, Cerullo V, Hemminki A, Piccialli V, Zaccaria S, Mayol L, Piccialli G. Synthesis and biological evaluation of unprecedented ring-expanded nucleosides (RENs) containing the imidazo[4,5-d][1,2,6]oxadiazepine ring system. Chem Commun (Camb). 2012 Sep 25;48(74):9310-2. IF=6.3

 

27.   Hemminki O, Diaconu I, Cerullo V, Pesonen SK, Kanerva A, Joensuu T, Kairemo K, Laasonen L, Partanen K, Kangasniemi L, Lieber A, Pesonen S, Hemminki A. Ad3-hTERT-E1A, a Fully Serotype 3 Oncolytic Adenovirus, in Patients With Chemotherapy Refractory Cancer. Mol Ther. 2012 Sep;20(9):1821-30. doi: 10.1038/mt.2012.115. Epub 2012 Aug 7. IF=7.04

 

28.   Cerullo V*, Diaconu I, Romano V, Hirvinen M, Ugolini M, Escutenaire S, Holm SL, Kipar A, Kanerva A, Hemminki A. An Oncolytic Adenovirus Enhanced for Toll-like Receptor 9 Stimulation Increases Antitumor Immune Responses and Tumor Clearance.  Mol Ther. 2012 Jul 24. IF=7.4

 

29.   Diaconu I, Cerullo V, Hirvinen ML, Escutenaire S, Ugolini M, Pesonen SK, Bramante S, Parviainen S, Kanerva A, Loskog AS, Eliopoulos AG, Pesonen S, Hemminki A. Immune response is an important aspect of the antitumor effect produced by a CD40L-encoding oncolytic adenovirus. Cancer Res. 2012 May 1;72(9):2327-38. IF=8.6

 

30.   Pesonen S, Diaconu I, Kangasniemi L, Ranki T, Kanerva A, Pesonen SK, Gerdemann U, Leen AM, Kairemo K, Oksanen M, Haavisto E, Holm SL, Karioja-Kallio A, Kauppinen S, Partanen KP, Laasonen L, Joensuu T, Alanko T, Cerullo V, Hemminki A. Oncolytic immunotherapy of advanced solid tumors with a CD40L-expressing replicating adenovirus: assessment of safety and immunologic responses in patients. Cancer Res. 2012 Apr 1;72(7):1621-31. IF=8.6

 

31.   Dias JD, Hemminki O, Diaconu I, Hirvinen M, Bonetti A, Guse K, Escutenaire S,  Kanerva A, Pesonen S, Löskog A, Cerullo V*, Hemminki A. Targeted cancer immunotherapy with oncolytic adenovirus coding for a fully human monoclonal antibody specific for CTLA-4. Gene Ther. 2012 Oct;19(10):988-98. IF=4.3

 

32.   Kangasniemi L, Parviainen S, Pisto T, Koskinen M, Jokinen M, Kiviluoto T, Cerullo V, Jalonen H, Koski A, Kangasniemi A, Kanerva A, Pesonen S, Hemminki A. Effects of capsid-modified oncolytic adenoviruses and their combinations with gemcitabine or silica gel on pancreatic cancer. Int J Cancer. 2012 Jul 1;131(1):253-63. IF=6.1

 

33.   Liikanen I, Monsurrò V, Ahtiainen L, Raki M, Hakkarainen T, Diaconu I, Escutenaire S, Hemminki O, Dias JD, Cerullo V, Kanerva A, Pesonen S, Marzioni D,  Colombatti M, Hemminki A. Induction of interferon pathways mediates in vivo resistance to oncolytic adenovirus. Mol Ther. 2011 Oct;19(10):1858-66. IF=7.04

 

34.   Tong AW, Senzer N, Cerullo V, Templeton NS, Hemminki A, Nemunaitis J. Oncolytic viruses for induction of anti-tumor immunity. Curr Pharm Biotechnol. 2012 Jul;13(9):1750-60.

 

35.   Cerullo V, Diaconu I, Kangasniemi L, Rajecki M, Escutenaire S, Koski A, Romano V, Rouvinen N, Tuuminen T, Laasonen L, Partanen K, Kauppinen S, Joensuu T, Oksanen M, Holm SL, Haavisto E, Karioja-Kallio A, Kanerva A, Pesonen S, Arstila PT, Hemminki A. Immunological effects of low-dose cyclophosphamide in cancer patients treated with oncolytic adenovirus. Mol Ther. 2011 Sep;19(9):1737-46. IF=7.04

 

36.   Pesonen S, Diaconu I, Cerullo V, Escutenaire S, Raki M, Kangasniemi L, Nokisalmi P, Dotti G, Guse K, Laasonen L, Partanen K, Karli E, Haavisto E, Oksanen M, Karioja-Kallio A, Hannuksela P, Holm SL, Kauppinen S, Joensuu T, Kanerva A, Hemminki A. Integrin targeted oncolytic adenoviruses Ad5-D24-RGD and Ad5-RGD-D24-GMCSF for treatment of patients with advanced chemotherapy refractory solid tumors. Int J Cancer. IF=6.1

 

37.   Suzuki M, Cela R, Bertin TK, Sule G, Cerullo V, Rodgers JR, Lee B. NOD2 signaling contributes to the innate immune response against helper-dependent adenovirus vectors independently of MyD88 in vivo. Hum Gene Ther. 2011 Sep;22(9):1071-82. IF=7.04

 

38.   Raki M, Sarkioja M, Escutenaire S, Kangasniemi L, Haavisto E, Kanerva A, Cerullo V, Joensuu T, Oksanen M, Pesonen S, Hemminki A. Switching the fiber knobof oncolytic adenoviruses to avoid neutralizing antibodies in human cancer patients. J Gene Med. 2011 May;13(5):253-61. IF=2.1

 

39.   Guse K, Cerullo V, Hemminki A. Oncolytic vaccinia virus for the treatment ofcancer. Expert Opin Biol Ther. 2011 May;11(5):595-608. Epub 2011 Feb 22. Review. 

 

40.   Escutenaire S, Cerullo V, Diaconu I, Ahtiainen L, Hannuksela P, Oksanen M, Haavisto E, Karioja-Kallio A, Holm SL, Kangasniemi L, Ribacka C, Kauppinen S, Joensuu T, Arstila TP, Pesonen S, Kanerva A, Hemminki A. In vivo and in vitro distribution of type 5 and fiber-modified oncolytic adenoviruses in human blood compartments. Ann Med. 2011 Mar;43(2):151-63.

 

41.   Hemminki O, Bauerschmitz G, Hemmi S, Lavilla-Alonso S, Diaconu I, Guse K, Koski A, Desmond RA, Lappalainen M, Kanerva A, Cerullo V, Pesonen S, Hemminki A.  Oncolytic adenovirus based on serotype 3. Cancer Gene Ther. 2011 Apr;18(4):288-96. IF=2.9

 

42.   Ahtiainen L, Mirantes C, Jahkola T, Escutenaire S, Diaconu I, Osterlund P, Kanerva A, Cerullo V, Hemminki A. Defects in innate immunity render breast cancer initiating cells permissive to oncolytic adenovirus. PLoS One. 2010 Nov 5;5(11):e13859. IF=3.7

 

43.   Rajecki M, Raki M, Escutenaire S, Pesonen S, Cerullo V, Helminen A, Hannuksela P, Partanen K, Laasonen L, Joensuu T, Kangasniemi L, Haavisto E, Kanerva A, Ahtiainen L, Hemminki A. Safety of glucocorticoids in cancer patientstreated with oncolytic adenoviruses. Mol Pharm. 2011 Feb 7;8(1):93-103. Epub 2010 Nov 8.

 

44.  Piccialli V, Zaccaria S, Borbone N, Oliviero G, D’Errico S, Hemminki A, Cerullo V, Romano V, Tuzi A, Centore R. Discovery of a novel one-step RuO4-catalysed tandem oxidative polycyclization/double spiroketalization process. Access to a new type of polyether bis-spiroketal compound displaying antitumour activity. Tetrahedron Volume 66, Issue 48, 27 November 2010, Pages 9370-937. IF=2.8

 

45.   Ahonen MT, Diaconu I, Pesonen S, Kanerva A, Baumann M, Parviainen ST, Spiller B, Cerullo V, Hemminki A. Calcium gluconate in phosphate buffered saline increases gene delivery with adenovirus type 5. PLoS One. 2010 Sep 30;5(9). IF=3.7

 

46.   Koski A, Kangasniemi L, Escutenaire S, Pesonen S, Cerullo V, Diaconu I, Nokisalmi P, Raki M, Rajecki M, Guse K, Ranki T, Oksanen M, Holm SL, Haavisto E,  Karioja-Kallio A, Laasonen L, Partanen K, Ugolini M, Helminen A, Karli E, Hannuksela P, Pesonen S, Joensuu T, Kanerva A, Hemminki A. Treatment of cancer patients with a serotype 5/3 chimeric oncolytic adenovirus expressing GMCSF. MolTher. 2010 Oct;18(10):1874-84. Epub 2010 Jul 27. IF=7.04

 

47.   Nokisalmi P, Pesonen S, Escutenaire S, Särkioja M, Raki M, Cerullo V, Laasonen L, Alemany R, Rojas J, Cascallo M, Guse K, Rajecki M, Kangasniemi L, Haavisto E, Karioja-Kallio A, Hannuksela P, Oksanen M, Kanerva A, Joensuu T, Ahtiainen L, Hemminki A. Oncolytic adenovirus ICOVIR-7 in patients with advancedand refractory solid tumors. Clin Cancer Res. IF=7.8

 

48.   Cerullo V, Pesonen S, Diaconu I, Escutenaire S, Arstila PT, Ugolini M, Nokisalmi P, Raki M, Laasonen L, Särkioja M, Rajecki M, Kangasniemi L, Guse K, Helminen A, Ahtiainen L, Ristimäki A, Räisänen-Sokolowski A, Haavisto E, OksanenM, Karli E, Karioja-Kallio A, Holm SL, Kouri M, Joensuu T, Kanerva A, Hemminki A. Oncolytic adenovirus coding for granulocyte macrophage colony-stimulating factorinduces antitumoral immunity in cancer patients. Cancer Res. IF=8.6

 

49.   Diaconu I, Cerullo V, Escutenaire S, Kanerva A, Bauerschmitz GJ, Hernandez-Alcoceba R, Pesonen S, Hemminki A. Human adenovirus replication in immunocompetent Syrian hamsters can be attenuated with chlorpromazine or cidofovir. J Gene Med. 2010 May;12(5):435-45. IF=2.7

 

50.   Dias JD, Liikanen I, Guse K, Foloppe J, Sloniecka M, Diaconu I, Rantanen V, Eriksson M, Hakkarainen T, Lusky M, Erbs P, Escutenaire S, Kanerva A, Pesonen S,  Cerullo V*, Hemminki A. Targeted chemotherapy for head and neck cancer with a chimeric oncolytic adenovirus coding for bifunctional suicide protein FCU1. ClinCancer Res. 2010 May 1;16(9):2540-9. IF=7.8

 

51.   Pesonen S, Nokisalmi P, Escutenaire S, Särkioja M, Raki M, Cerullo V, Kangasniemi L, Laasonen L, Ribacka C, Guse K, Haavisto E, Oksanen M, Rajecki M, Helminen A, Ristimäki A, Karioja-Kallio A, Karli E, Kantola T, Bauerschmitz G, Kanerva A, Joensuu T, Hemminki A. Prolonged systemic circulation of chimeric oncolytic adenovirus Ad5/3-Cox2L-D24 in patients with metastatic and refractory solid tumors. Gene Ther. 2010 Jul;17(7):892-904. IF=4.3

 

52.   Dias JD, Guse K, Nokisalmi P, Eriksson M, Chen DT, Diaconu I, Tenhunen M, Liikanen I, Grénman R, Savontaus M, Pesonen S, Cerullo V*, Hemminki A. Multimodalapproach using oncolytic adenovirus, cetuximab, chemotherapy and radiotherapy inHNSCC low passage tumour cell cultures. Eur J Cancer. 2010 Feb;46(3):625-35. IF=5.06

 

53.   Guse K, Sloniecka M, Diaconu I, Ottolino-Perry K, Tang N, Ng C, Le Boeuf F, Bell JC, McCart JA, Ristimäki A, Pesonen S, Cerullo V, Hemminki A. Antiangiogenic arming of an oncolytic vaccinia virus enhances antitumor efficacy in renal cell cancer models. J Virol. 2010 Jan;84(2):856-66. Epub 2009 Nov 11. IF=5.0

 

 

54.   Suzuki M, Cerullo V, Bertin TK, Cela R, Clarke C, Guenther M, Brunetti-Pierri N, Lee B. MyD88-dependent silencing of transgene expression during the innate and adaptive immune response to helper-dependent adenovirus. Hum Gene Ther. 2010 Mar;21(3):325-36. IF=4.0

 

 

55.   Pesonen S, Helin H, Nokisalmi P, Escutenaire S, Ribacka C, Sarkioja M, Cerullo V, Guse K, Bauerschmitz G, Laasonen L, Kantola T, Ristimaki A, Rajecki M, Oksanen M, Haavisto E, Kanerva A, Joensuu T, Hemminki A. Oncolytic adenovirus treatment of a patient with refractory neuroblastoma. Acta Oncol. 2010;49(1):117-9. IF=2.8

 

56.  Piccialli V, Oliviero G, Borbone N, Tuzi A, Centore R, Hemminki A, Ugolini M, Cerullo V. Discovery of a new PCC-mediated stereoselective oxidative spiroketalization process. An access to a new type of poly-THF spiroketal compound displaying anticancer activity. Organic & Biomolecular Chemistry. 2009;7(15):3036-9. IF=3.5

 

57.   Gau CL, Rosenblatt RA, Cerullo V, Lay FD, Dow AC, Livesay J, Brunetti-PierriN, Lee B, Cederbaum SD, Grody WW, Lipshutz GS. Short-term correction of arginasedeficiency in a neonatal murine model with a helper-dependent adenoviral vector.  Mol Ther. 2009 Jul;17(7):1155-63. Epub 2009 Apr 14. IF=7.04

 

58.   Diaconu I, Denby L, Pesonen S, Cerullo V, Bauerschmitz GJ, Guse K, Rajecki M, Dias JD, Taari K, Kanerva A, Baker AH, Hemminki A. Serotype chimeric and fiber-mutated adenovirus Ad5/19p-HIT for targeting renal cancer and untargeting the liver. Hum Gene Ther. 2009 Jun;20(6):611-20. IF=4.0

 

59.   Brunetti-Pierri N, Grove NC, Zuo Y, Edwards R, Palmer D, Cerullo V, Teruya J, Ng P. Bioengineered factor IX molecules with increased catalytic activity improve the therapeutic index of gene therapy vectors for hemophilia B. Hum Gene Ther. 2009 May;20(5):479-85. IF=4.0

 

60.   Wang CE, Zhou H, McGuire JR, Cerullo V, Lee B, Li SH, Li XJ. Suppression of neuropil aggregates and neurological symptoms by an intracellular antibody implicates the cytoplasmic toxicity of mutant huntingtin. J Cell Biol. 2008 Jun 2;181(5):803-16. Epub 2008 May 26. IF=10.8

 

61.   Cerullo V, McCormack W, Seiler M, Mane V, Cela R, Clarke C, Rodgers JR, Lee B. Antigen-specific tolerance of human alpha1-antitrypsin induced by helper-dependent adenovirus. Hum Gene Ther. 2007 Dec;18(12):1215-24. IF=4.0

 

62.   Seiler MP, Cerullo V, Lee B. Immune response to helper dependent adenoviral mediated liver gene therapy: challenges and prospects. Curr Gene Ther. 2007 Oct;7(5):297-305. Review.

 

63.   Cerullo V, Seiler MP, Mane V, Cela R, Clarke C, Kaufman RJ, Pipe SW, Lee B. Correction of murine hemophilia A and immunological differences of factor VIII variants delivered by helper-dependent adenoviral vectors. Mol Ther. 2007 Dec;15(12):2080-7. IF=7.04

 

64.   Seiler MP, Gottschalk S, Cerullo V, Ratnayake M, Mane VP, Clarke C, Palmer DJ, Ng P, Rooney CM, Lee B. Dendritic cell function after gene transfer with adenovirus-calcium phosphate co-precipitates. Mol Ther. 2007 Feb;15(2):386-92. IF=7.04

 

65.   Cerullo V, Seiler MP, Mane V, Brunetti-Pierri N, Clarke C, Bertin TK, Rodgers JR, Lee B. Toll-like receptor 9 triggers an innate immune response to helper-dependent adenoviral vectors. Mol Ther. 2007 Feb;15(2):378-85. IF=7.04

 

66.   Iaccarino G, Ciccarelli M, Sorriento D, Galasso G, Campanile A, Santulli G, Cipolletta E, Cerullo V, Cimini V, Altobelli GG, Piscione F, Priante O, Pastore L, Chiariello M, Salvatore F, Koch WJ, Trimarco B. Ischemic neoangiogenesis enhanced by beta2-adrenergic receptor overexpression: a novel role for the endothelial adrenergic system. Circ Res. 2005 Nov 25;97(11):1182-9. IF=11.8

 

67.   Croyle MA, Le HT, Linse KD, Cerullo V, Toietta G, Beaudet A, Pastore L. PEGylated helper-dependent adenoviral vectors: highly efficient vectors with an enhanced safety profile. Gene Ther. 2005 Apr;12(7):579-87. IF=4.0

 

68.   Iaccarino G, Ciccarelli M, Sorriento D, Cipolletta E, Cerullo V, Iovino GL, Paudice A, Elia A, Santulli G, Campanile A, Arcucci O, Pastore L, Salvatore F, Condorelli G, Trimarco B. AKT participates in endothelial dysfunction in hypertension. Circulation. 2004 Jun 1;109(21):2587-93. IF=15.2

 

69.   Toietta G, Pastore L, Cerullo V, Finegold M, Beaudet AL, Lee B. Generation of helper-dependent adenoviral vectors by homologous recombination. Mol Ther. 2002Feb;5(2):204-10. IF=7.04

70.